TABLE 2.

Days since first dose and anti-SARS-CoV-2 IgG titers for mRNA-1273 and BNT162b2 following the first and second doses^a

No. of days since first dose (range)	mRNA-1273		BNT162b2
	No. of days since first dose (median)	Mean IgG (BAU/mL)	No. of days since first dose (median)	Mean IgG (BAU/mL)
0–6	0	3.78	0	0
7–13	9	67.50	10	166.23
14–20	16	313.69b	18	167.91
21–27	23	414.12	24.5	421.76
28–34	33	528.55	33	760.43b
35–41	39	887.50	38	899.87
42–48	45	876.96b	47	766.75
49–55	52	814.58	51	751.41
56–62	58	724.21	59	687.90
63–69	65	713.13	66	640.46
70–76	72	659.97b	74	566.27
77–83	79.5	618.40b	79	501.30

^aBNT162b2 delivers 30 μg of mRNA and is boosted 3 weeks after the first dose. mRNA-1273 delivers 100 μg of mRNA and is boosted 4 weeks after the first dose. BAU/mL, binding antibody units/mL.

^bTiters were significantly higher for this vaccine at that time point.